Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols

Cancer

Volumn 120, Issue 24, 2014, Pages 3958-3964

  Motlló, Cristina ^a   Ribera, Josep María ^a   Morgades, Mireia ^a   Granada, Isabel ^a   Montesinos, Pau ^b   González Campos, José ^c   Fernández Abellán, Pascual ^d   Tormo, Mar ^e   Bethencourt, Concepción ^f   Brunet, Salut ^g   Hernández Rivas, Jesús María ^h   Moreno, María José ⁱ   Sarrá, Josep ^j   Del Potro, Eloy ^k   Barba, Pere ^l   Bernal, Teresa ^m   Grande, Carlos ⁿ   Grau, Javier ^a   Cervera, José ^b   Feliu, Evarist ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^j HOSPITAL DURAN I REYNALS   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

Acute lymphoblastic leukemia; Adults; Complex karyotype; Monosomal karyotype; Prognosis

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL PROTOCOL; COMPLEX KARYOTYPE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMAL KARYOTYPE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; GENETICS; KARYOTYPING; MIDDLE AGED; MONOSOMY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; REMISSION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BENZAMIDES; FEMALE; HUMANS; KARYOTYPE; KARYOTYPING; MALE; MIDDLE AGED; MONOSOMY; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIMIDINES; REMISSION INDUCTION; RISK ADJUSTMENT; YOUNG ADULT;

EID: 84919348129     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28950     Document Type: Article

References (21)

1. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007; 109: 3189-3197.
2. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMEA 0469 protocol. Blood. 2005; 105: 3434-3441.
3. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008; 111: 2563-2572.
4. Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 TRIAL. Haematologica. 2002; 87: 154-166.
5. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trial UKALL XA. Br J Haematol. 1997; 96: 601-610.
6. Wetzler M, Dodge RK, Mrózek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999; 93; 3983-3993.
7. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008; 26: 4791-4797.
8. Breems DA, Löwenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica. 2011; 96: 491-493.
9. Haferlach C, Alpermann T, Schnittger S, et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood. 2012; 119: 2122-2125.
10. Kenderian SS, Al-Kali A, Gangat N, et al. Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood Cancer J. 2013; 3: e122.
11. Shaffer LG, Slovak ML, Campbell LJ, eds. ISCN 2013: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2013.
12. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espa~nol de tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol. 2008; 26: 1843-1849.
13. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005; 90: 1346-1356.
14. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk (HR) Philadelphia chromosome-negative (Ph-) adult acute lymphoblastic leukemia in adolescents and adults according to early cytological response and minimal residual disease after consolidation assessed by flow cytometry: Final results of PETHEMA ALL-HR-03 Trial. J Clin Oncol. 2014; 32: 1595-1604.
15. Ribera J M, García O, Fernández-Abellán P, et al. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two propective parallel protocols. Br J Haematol. 2012; 159: 485-488.
16. Ribera JM, Oriol A, González M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadeplhia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010; 95: 87-95.
17. Ribera JM, García O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol. 2012; 159: 78-81.
18. Oriol A, Ribera JM, Esteve J, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003; 88: 445-453.
19. Ribera JM, García O, Grande C, et al. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab).Cancer. 2013; 119: 1660-1668.
20. Medeiros BC, Tohus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010; 116: 2224-2228.
21. Yang XF, Sun AN, Yin J, et al. Monosomal karyotype among 1147 Chinese patients with acute myeloid leukemia : prevalence, features and prognostic impact. Asian Pac J Cancer Prev. 2012; 13: 5421-5426.